Pro Medicus Posts 40.5% Profit Growth, Declares Higher Dividend
Pro Medicus Limited has reported a robust FY25 with revenue climbing nearly 32% and net profit up 39%, prompting a significant dividend increase.
- Revenue rises 31.9% to A$213 million
- Underlying profit before tax grows 40.5%
- Net profit after tax increases 39.2%
- Final dividend raised to 30 cents per share, fully franked
- No changes in control or associates reported
Strong Financial Growth
Pro Medicus Limited, a key player in the medical software sector, has delivered an impressive financial performance for the year ended 30 June 2025. The company’s revenue surged by 31.9% to A$212.98 million, reflecting robust demand for its healthcare imaging solutions. Underlying profit before tax, excluding currency fluctuations and fair value movements, rose even more sharply by 40.5% to A$157.69 million, underscoring operational efficiency and strong market positioning.
Profitability and Dividend Highlights
The reported profit before tax reached A$163.31 million, boosted by favorable fair value adjustments, while net profit after tax attributable to members increased by 39.2% to A$115.22 million. This solid earnings growth has translated into enhanced returns for shareholders, with the board declaring a fully franked final dividend of 30.0 cents per share, up from 22.0 cents the previous year. The final dividend is scheduled for payment on 25 September 2025, following an interim dividend of 25.0 cents paid earlier in the year.
Operational Stability and Outlook
Pro Medicus reported no changes in control of entities or associates during the period, indicating operational stability. The company’s net tangible assets per security decreased from $2.26 to $1.61, a figure that warrants further analysis once the full financial statements are reviewed. CEO Sam Hupert signed off on the audited accounts, which reflect a disciplined approach to growth and shareholder returns.
Market Implications
This strong set of results positions Pro Medicus well within the competitive healthcare technology landscape. The significant uplift in revenue and profit, coupled with increased dividends, signals confidence in ongoing demand for its products and services. Investors will be watching closely for the detailed segment performance and any commentary on future trends when the full year accounts are released.
Bottom Line?
Pro Medicus’s robust FY25 results and dividend hike set the stage for close market attention as the company charts its next growth phase.
Questions in the middle?
- What are the drivers behind the sharp increase in revenue and profit?
- How will the decline in net tangible assets per security impact investor sentiment?
- What insights will the full financial statements provide on segment performance and future outlook?